ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
12 announcements with these filters
SMS Pharmaceuticals disclosed two market sell trades by Designated Person NVV Satyanarayana totalling ₹0.14 Crore. The PIT Reg 7(2) intimation involves a non-promoter designated person.
SMS Pharmaceuticals Limited has scheduled its 38th Annual General Meeting for September 29, 2026. Key agenda items include dividend declaration, management re-appointments, and approval of material related party transactions.
SMS Pharmaceuticals Limited has released its Annual Report and Notice for the 38th Annual General Meeting scheduled for September 29, 2026. The company reported FY26 revenue of ₹887 Crore.
CARE Ratings Limited has reaffirmed or revised the credit ratings for SMS Pharmaceuticals Limited's bank facilities. The review covers the company's long-term and short-term credit facilities.
SMS Pharmaceuticals Limited has rescheduled its 38th Annual General Meeting to September 29, 2026. Consequently, the record date for the FY 2025-26 dividend is revised to September 22, 2026.
N. Srilakshmi Padmini, an employee's immediate relative, purchased 3,000 equity shares of SMS Pharmaceuticals for ₹0.11 Crore via market purchase.
SMS Pharma reported Q1FY27 revenue of ₹207 Cr (+6% YoY) with stable EBITDA margins at ~20%. Strategy focuses on high-value APIs and peptide R&D.
SMS Pharmaceuticals reported Q1FY27 revenue of ₹207 crore, up 6% YoY. The board also approved a ₹50 crore loan infusion into its subsidiary, SMS Peptides.
SMS Pharmaceuticals has re-appointed Mr. Ramesh Babu Potluri as Executive Director for a 60-month term effective October 1, 2026.
SMS Pharmaceuticals Ltd reported revenue from operations of ₹207 Cr (+5.6% YoY) and net profit of ₹20.9 Cr (+2.0% YoY) for Q1 FY27.
SMS Pharmaceuticals has scheduled a board meeting for August 1, 2026, to consider and approve the financial results for the quarter ended June 30, 2026.
SMS Pharmaceuticals updated the exchange regarding an ongoing police investigation into a prior impersonation case. One suspect has been arrested and remanded into judicial custody.